Penumbra

History

2026: Boston Scientific bought Penumbra for $14.5 billion

On January 15, 2026, Boston Scientific announced an agreement to acquire heart disease device maker Penumbra. The deal is worth $14.5 billion, the largest purchase in Boston Scientific history.

Penumbra offers innovative solutions for mechanical thrombectomy (designed to remove blood clots that cause blockage of arterial, venous and pulmonary vessels), computer vacuum thrombectomy systems, and a minimally invasive peripheral embolization system designed to stop blood flow in vascular interventions. In addition, the company's assortment includes neurovascular products for revascularization in stroke and neuroembolization.

𝓲

Фото: Penumbra

Under the terms of an agreement approved by the boards of directors of both companies, each Penumbra share is valued at $374. In the overall structure of the transaction, about 73% is expected to be cash, the remaining 27% is Boston Scientific securities. At the same time, Penumbra shareholders can choose between receiving money in the amount of $374 for each share or 3.8721 ordinary shares of Boston Scientific. Completion of the transaction is expected in 2026, subject to receiving approval from Penumbra shareholders and meeting standard regulatory requirements.

As Mike Mahoney, Chairman and CEO of Boston Scientific, notes, the acquisition of Penumbra will allow the company to enter the rapidly growing segments of the cardiovascular disease market. In the long term, this will help increase revenue and profit. It is emphasized that Penumbra has developed a comprehensive set of solutions involving differentiated devices for the treatment of conditions such as pulmonary embolism, stroke, deep vein thrombosis, acute limb ischemia, myocardial infarction and aneurysms.^[1]

Notes